RESUMO
ObjectiveTo observe the efficacy and safety of house dust mite vaccine in the treatment of house dust mite-allergic rhinitis.Methods47 patients with allergic rhinitis were recruited into the study.The course of SIT was treated by house dust mite vaccine for 51 weeks.Self-contrast method was used to compare the symptom score,nasal airway resistance before and after treatment.Then we observed the security in the process of injection.ResultsThe symptom score was (7.40 ± 1.64) vs ( 3.40 ± 1.50 ) pre and post therapy.Nasal airway resistance were (2.02 ±0.72) vs ( 1.06 ± 0.81 ) kPa · s -1 · L-1.Both the values of the data had significant differences( t =15.49,4.44,all P ＜ 0.01 ).No serious adverse reaction was observed.ConclusionSIT was able to improve the clinical symptoms and decrease nasal airway resistance.House dust mite vaccine was an effect and safe drug for the dust mite allergic asthma patients.
RESUMO
Background: The prevalence of allergic diseases, particularly asthma and allergic rhinitis, has increased tremendously in Thailand and worldwide. House dust mite (HDM) is the major IgE sensitizer among allergic children and adults. We have developed local standardized mite allergen extracts, Siriraj Mite Allergen Vaccine (SMAV) from Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df) from our source materials which were highly purified (99%). Objective: To compare in-vivo allergenic potency of both SMAV Dp and Df with commercial standardized mite allergen vaccine by using skin prick testing in mite-sensitive individuals. Methods: This was a double-blind, randomized, self controlled study comparing SMAV and commercial standardized mite allergen vaccine (Dp and Df) by using skin prick testing in mite-sensitive adult volunteers, 18 – 60 years of age. Results: The study was performed in 54 adult volunteers (19 males, mean age 26.6 + 5.5 years old) who had positive skin test to commercial Dp and Df. Seventeen of them had no allergic disease. The most common allergic disease among the volunteers was allergic rhinitis (21/37). Mean wheal diameter of SMAV Dp and commercial Dp at the concentration of 10,000 and 5, 000 AU/ml were equivalent but at the concentration of 2,500 AU/ml was inequivalent. Mean wheal diameter of SMAV Dp was significantly larger than commercial Dp at concentration of 2,500 AU/ml (p < 0.05). Mean wheal diameter of SMAV Df and commercial Df at all 3 concentrations were equivalent. There was no systemic side effect in all subjects. Conclusion: The study demonstrated that in mite-sensitive adults, SPT using SMAV Dp (10,000 AU) and Df (10,000 AU) had equivalent allergenic potency to the commercial comparator without any systemic side effect.
RESUMO
0.05).Conclution:The NHD house can modulate a imbalanced status of Th1/Th2 cells,Some common antigens are contained in both the dermatophagoides pteronyssinus and other allergens:pollen,fungus,et al,which are able to combine with the specific antibodies in serum.This study provides a theoretical basis for the allergen-specific immunotherapy for allergic rhinitis.